Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: Part II-A method of software documentary analysis

Stem Cells Translational Medicine

Volumn 1, Issue 12, 2012, Pages 909-920

  Ilic, Nina ^a,b   Savic, Snezana ^a   Siegel, Evan ^c   Atkinson, Kerry ^d,e   Tasic, Ljiljana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b MATER HOSPITAL   (Australia)

^c Ground Zero Pharmaceuticals   (United States)

^d MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cellular therapy; Clinical translation; Clinical trials; Ethics

Indexed keywords

BIOLOGICAL PRODUCT;

ARTICLE; AUSTRALIA; CLINICAL PRACTICE; COMPARATIVE STUDY; DATA ANALYSIS SOFTWARE; DOCUMENTATION; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; PRACTICE GUIDELINE; QUALITATIVE RESEARCH; STEM CELL; UNITED STATES; ANIMAL; COMPUTER PROGRAM; LEGAL ASPECT; NOMENCLATURE; STANDARD; STEM CELL TRANSPLANTATION;

ANIMALS; AUSTRALIA; BIOLOGICAL AGENTS; DOCUMENTATION; EUROPE; HUMANS; SOFTWARE; STEM CELL TRANSPLANTATION; TERMINOLOGY AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

MLCS; MLOWN;

EID: 84872946357     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0038     Document Type: Article

References (49)

1. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006; 355:1730-1735.
2. FDA Guidance for industry: PAT-A framework for innovative pharmaceutical development, manufacturing, and quality assurance. 2004. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070305.pdf. Accessed January 13, 2011.
3. The Financing of Biopharmaceutical Product Development in Europe. Final Report. European Commission, Enterprise and Industry. October 2009. Available at http://ec.europa.eu/enterprise/sectors/biotechnology/files/docs/financing_biopharma_product_dev_en.pdf. Accessed December 5, 2011.
4. Advancing Regulatory Science at FDA, Strategic Plan: August 2011. Food and Drug Administration, U.S. Department of Health and Human Services. Available at http://www.fda.gov/regulatoryscience. Accessed December 5, 2011.
5. Implementing the European Medicines Agency's Road Map to 2015: The Agency's Contribution to Science, Medicine, Health-From Vision to Reality. EMA/MB/550544/2011. October 6, 2011. Available at http://www.ema.europa.eu. Accessed November 22, 2011.
6. Burger SR. Current regulatory issues in cell and tissue therapy. Cytotherapy 2003;5:289-298.
7. TGA basics. Therapeutic Goods Administration. Available at http://www.tga.gov.au/about/tga.htm. Accessed September 1, 2011.
8. Clinical trials. Therapeutic Goods Administration. Available at http://www.tga.gov.au/industry/clinical-trials.htm. Accessed September 1, 2011.
9. Clinical trials at a glance. Therapeutic Goods Administration. Available at http://www.tga.gov.au/industry/clinical-trials-glance.htm. Accessed September 1, 2011.
10. Note for guidance on good clinical practice. Therapeutic Goods Administration. Available at http://www.tga.gov.au/industry/clinical-trials-note-ich13595.htm. Accessed August 6, 2011.
11. European Medicines Agency. Available at http://www.ema.europa.eu/ema. Accessed October 15, 2011.
12. About us. European Medicines Agency. Available at http://www.ema.europa.eu/ema/index.jsp?curlpages/about_us/general/general_content_000235.jsp&murlmenus/about_us/about_us.jsp. Accessed October 15, 2011.
13. Food and Drug Administration. Available at http://www.fda.gov. Accessed October 27, 2011.
14. Development & Approval Process (CBER). Center for Biologics Evaluation and Research, Food and Drug Administration. Available at http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/default.htm. Accessed July 20, 2011.
15. The Center for Drug Evaluation and Research (CDER), Food and Drug Administration. Guidance, compliance, and regulatory information. Available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/default.htm. Accessed July 20, 2011.
16. New Drug Application (NDA) Process (CBER). Center for Biologics Evaluation and Research, Food and Drug Administration. Available at http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/NewDrugApplicationNDAProcess/default.htm. Accessed July 21, 2011.
17. Ilic N, Savic S, Siegel E et al. Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: Part I-A method of manual documentary analysis. STEM CELLS TRANSLATIONAL MEDICINE 2012; 1:898-908.
18. Mason J. Qualitative Researching. 2nd ed. London, UK: Sage Publications, 2002.
19. Smith AE. Leximancer tutorials. Available at https://www.leximancer.com/support/. Accessed August 2, 2011.
20. Bailey KD. Methods of Social Research. 2nd ed. New York, NY: Free Press, 1982.
21. Robson C. Real World Research. 2nd ed. Oxford, U.K.: Blackwell, 2002.
22. Smith AE. Leximancer Manual (Version 2.2) 2005. Available at https://www.leximancer.com/wiki/images/7/77/Leximancer_V2_Manual.pdf. Accessed August 2, 2011.
23. Weber RP. Basic Content Analysis. 2nd ed. Thousand Oaks, CA: Sage Publications, 1990.
24. Cabré Castellví MT. Theories of terminology: Their description, prescription and explanation. Terminology 2003;9:163-199.
25. Meyer I, Eck K, Skuce D. Systematic concept analysis within a knowledge-based approach to terminology. In: Wright SE, Buding G, eds. Handbook of Terminology Management. Amsterdam, The Netherlands: John Benjamins, 1997:110.
26. Felber H. Terminology Manual. Paris: General Information Programme & UNISIST, UNESCO. Paris, France: Infoterm, 1984.
27. Kageura K. The Dynamics of Terminology: A Descriptive Theory of Term Formation and Terminological Growth. Amsterdam, The Netherlands: John Benjamins, 2002.
28. Ilic N, Khalil D, Hancock S et al. Regulatory considerations applicable to manufacturing of human placenta-derived mesenchymal stromal cells (MSC) used in clinical trials in Australia and comparison to USA and European regulatory frameworks. Mesenchymal Stem Cell Therapy. Springer/Humana Press (in press).
29. Smith AE, Humphreys MS. Evaluation of unsupervised semantic mapping of natural language with Leximancer concept mapping. Behav Res Methods 2006;38:262-279.
30. Cretchley J, Gallois C, Chenery H et al. Conversations between carers and people with schizophrenia: A qualitative analysis using Leximancer. Qual Health Res 2010;20: 1611-1628.
31. McKenna B, Waddell N. Media-ted political oratory following terrorist events. J Lang Pol 2007;6:377-399.
32. Martin NJ, Rice JL. Profiling enterprise risks in large computer companies using the Leximancer software tool. Risk Manag 2007;9: 188-206.
33. Scott N, Smith AE. Use of automated content analysis techniques for event image assessment. Tourism Recreation Res 2005;30: 87-91.
34. Grech MR, Horberry T, Smith AE. Human error in maritime operations: Analyzes of accidents reports using the Leximancer tool. Presented at the Human Factor and Ergonomics Society 46th Annual Meeting, Baltimore, MD, 2002.
35. Loke K, Bartlett B. What distinguishes a distinction? Perceptions of quality academic performance and strategies for achieving it. In: Reimagining Practice: Researching Change, Vol. 2. Conference Proceedings of the International Conference on Cognition, Language, and Special Education. Nathan, QLD, Australia: Griffith University, 2003; 175-182.
36. Rooney D, Gallois C, Cretchley J. Mapping a 40-year history with Leximancer: Themes and concepts in the Journal of Cross-Cultural Psychology. J Cross-Cultural Psychol 2010;41;318-328.
37. Baker SC, Gallois C, Driedger SM et al. Communication accommodation and managing musculoskeletal disorders: doctors' and patients' perspectives. Health Commun 2011;26: 379-388.
38. Kyle GJ, Nissen L, Tett S. Perception of prescription medicine sample packs among Australian professional, government, industry, and consumer organizations, based on automated textual analysis of one-on-one interviews. Clin Ther 2008;30:2461-2473.
39. Travaglia JF, Westbrook MT, Braithwaite J. Implementation of a patient safety incident management system as viewed by doctors, nurses and allied health professionals. Health (London) 2009;13:277-296.
40. Hepworth N, Paxton, SJ. Pathways to help-seeking in bulimia nervosa, binge eating problems: A concept mapping approach. Int J Eat Disord 2007;40:493-504.
41. McGivern G, Fischer MD. Reactivity and reactions to regulatory transparency in medicine, psychotherapy and counselling. Soc Sci Med 2012;74:289-296.
42. Noble C, O'Brien M, Coombes I et al. Concept mapping to evaluate an undergraduate pharmacy curriculum. Am J Pharm Educ 2011;75:55.
43. Watson M, Smith A, Watter S. Leximancer concept mapping of patient case studies. In: Khosla R, ed. Knowledge-Based Intelligent Information and Engineering Systems. Lecture Notes in Computer Science, Vol. 3683. Springer, 2005;1232-1238.
44. Grimbeek P, Bartlett B, Loke K. Using Leximancer to identify themes and patterns in the talk of three high-distinction students. In: Bartlett B, Bryer F, Roebuck D, eds. Second Annual Conference on Cognition, Language, and Special Education Research: Vol. 2: Educating: Weaving Research into Practice. Brisbane, QLD, Australia: Griffith University, 2004;122-128.
45. Zuell C, Harkness J, Juergen HP et al., eds. Computer-Assisted Text Analysis for the Social Sciences: The General Inquirer III. Manheim, Germany: Center for Surveys, Methods and Analysis (ZUMA), 1989.
46. Miles MB, Huberman AM. Qualitative Data Analysis. 2nd ed. Thousand Oaks, CA: Sage Publications, 1994.
47. Patton MQ. Qualitative Research & Evaluation Methods. 3rd ed. Thousand Oaks, CA: Sage Publications, 2002.
48. Creswell JW. Qualitative Inquiry & Research. 2nd ed. Thousand Oaks, CA: Sage Publications, 2007.
49. Maxwell JA. Qualitative Research Design. 2nd ed. Thousand Oaks, CA: Sage Publications, 2005.